Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins Hesham S. Al-SallamiMichael A. BarrasStephen B. Duffull Current Opinion 18 December 2012 Pages: 567 - 571
Dipeptidylpeptidase-4 Inhibitors (Gliptins) André J. Scheen Review Article 18 December 2012 Pages: 573 - 588
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model Gezim LahuAndreas HünnemeyerAxel Facius Original Research Article 18 December 2012 Pages: 589 - 606
Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment Angelika WeilPaul MartinKarl-Heinz Molz Original Research Article 18 December 2012 Pages: 607 - 618
Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans Zvi TeitelbaumThierry LaveAdam F. Cohen Original Research Article 18 December 2012 Pages: 619 - 632